Inogen (NASDAQ:INGN) Downgraded to “Sell” at StockNews.com

StockNews.com cut shares of Inogen (NASDAQ:INGN) from a hold rating to a sell rating in a research note released on Friday.

Several other equities analysts also recently commented on INGN. Needham & Company LLC reaffirmed a hold rating on shares of Inogen in a research report on Wednesday, May 8th. Stifel Nicolaus upped their price objective on Inogen from $6.00 to $7.00 and gave the company a hold rating in a research report on Wednesday, May 8th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of Hold and a consensus price target of $7.00.

Inogen Stock Performance

NASDAQ:INGN opened at $9.19 on Friday. The stock’s fifty day moving average is $8.41 and its 200 day moving average is $7.60. Inogen has a fifty-two week low of $4.13 and a fifty-two week high of $10.64. The firm has a market capitalization of $216.70 million, a PE ratio of -2.21 and a beta of 1.07.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, May 7th. The medical technology company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.14. The company had revenue of $78.03 million for the quarter, compared to the consensus estimate of $73.67 million. Inogen had a negative return on equity of 42.87% and a negative net margin of 30.07%. Inogen’s quarterly revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.63) EPS. Equities analysts forecast that Inogen will post -2.2 EPS for the current year.

Insider Transactions at Inogen

In other news, EVP Jason Somer sold 10,000 shares of the stock in a transaction on Friday, May 10th. The stock was sold at an average price of $8.56, for a total transaction of $85,600.00. Following the transaction, the executive vice president now owns 4,452 shares of the company’s stock, valued at approximately $38,109.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.99% of the company’s stock.

Institutional Investors Weigh In On Inogen

A number of institutional investors have recently added to or reduced their stakes in the stock. CWM LLC boosted its position in Inogen by 2,185.9% during the second quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock valued at $54,000 after purchasing an additional 6,339 shares in the last quarter. Stokes Family Office LLC boosted its position in Inogen by 162.1% during the second quarter. Stokes Family Office LLC now owns 113,985 shares of the medical technology company’s stock valued at $927,000 after purchasing an additional 70,500 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Inogen by 5.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 23,868 shares of the medical technology company’s stock valued at $193,000 after purchasing an additional 1,188 shares in the last quarter. Brown Capital Management LLC boosted its position in Inogen by 26.6% during the first quarter. Brown Capital Management LLC now owns 1,975,312 shares of the medical technology company’s stock valued at $15,941,000 after purchasing an additional 414,903 shares in the last quarter. Finally, Pitcairn Co. bought a new stake in Inogen during the first quarter valued at about $86,000. Institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.